Servier Acquires Rights to Black Diamond’s Solid Tumor Drug BDTX-4933 in $780M Deal

Servier and Black Diamond Therapeutics announced a global licensing agreement for BDTX-4933, a potential best-in-class targeted therapy for solid tumors1 2.

Deal terms include a $70 million upfront payment to Black Diamond and up to $710 million in additional development and commercial milestone payments, plus tiered royalties1 2 6.

BDTX-4933 is a Phase 1 asset targeting both RAS mutations and RAF alterations in solid tumors, including non-small cell lung cancer (NSCLC)1 2.

Servier will lead development activities and worldwide commercialization of BDTX-4933 across multiple indications1 2.

The drug is designed to address unmet medical needs in RAF/RAS-mutant solid tumors1 2.

BDTX-4933 is currently in a Phase 1 trial evaluating safety, tolerability, and antitumor activity in patients with recurrent advanced/metastatic cancers harboring BRAF, CRAF, or NRAS mutations10.

This deal comes after Black Diamond announced in October 2024 that it was deprioritizing BDTX-4933 development and seeking a partner to advance the drug10.

The agreement aligns with Servier's commitment to developing targeted therapies for oncology and addressing unmet medical needs1 2.

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations6 12.

This licensing deal represents a significant financial event for Black Diamond, potentially transforming the company's risk profile and providing capital strength11.